Literature DB >> 31127619

Immunity and hypertension: New targets to lighten the pressure.

Antony Vinh1, Grant R Drummond1, Christopher G Sobey1.   

Abstract

LINKED ARTICLES: This article is part of a themed section on Immune Targets in Hypertension. To view the other articles in this section visit http://onlinelibrary.wiley.com/doi/10.1111/bph.v176.12/issuetoc.
© 2019 The British Pharmacological Society.

Entities:  

Year:  2019        PMID: 31127619      PMCID: PMC6534776          DOI: 10.1111/bph.14659

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN: 0007-1188            Impact factor:   8.739


  50 in total

1.  The treatment of inflammatory arthritis with methotrexate in clinical practice: treatment duration and incidence of adverse drug reactions.

Authors:  A J Kinder; A B Hassell; J Brand; A Brownfield; M Grove; M F Shadforth
Journal:  Rheumatology (Oxford)       Date:  2005-01       Impact factor: 7.580

2.  Lymphocyte responses exacerbate angiotensin II-dependent hypertension.

Authors:  Steven D Crowley; Young-Soo Song; Eugene E Lin; Robert Griffiths; Hyung-Suk Kim; Phillip Ruiz
Journal:  Am J Physiol Regul Integr Comp Physiol       Date:  2010-02-10       Impact factor: 3.619

3.  Mononuclear phagocyte system depletion blocks interstitial tonicity-responsive enhancer binding protein/vascular endothelial growth factor C expression and induces salt-sensitive hypertension in rats.

Authors:  Agnes Machnik; Anke Dahlmann; Christoph Kopp; Jennifer Goss; Hubertus Wagner; Nico van Rooijen; Kai-Uwe Eckardt; Dominik N Müller; Joon-Keun Park; Friedrich C Luft; Dontscho Kerjaschki; Jens Titze
Journal:  Hypertension       Date:  2010-02-08       Impact factor: 10.190

4.  Central and peripheral mechanisms of T-lymphocyte activation and vascular inflammation produced by angiotensin II-induced hypertension.

Authors:  Paul J Marvar; Salim R Thabet; Tomasz J Guzik; Heinrich E Lob; Louise A McCann; Connie Weyand; Frank J Gordon; David G Harrison
Journal:  Circ Res       Date:  2010-06-17       Impact factor: 17.367

5.  Hypertension in response to autoantibodies to the angiotensin II type I receptor (AT1-AA) in pregnant rats: role of endothelin-1.

Authors:  Babbette LaMarca; Marc Parrish; Lillian Fournier Ray; Sydney R Murphy; Lyndsay Roberts; Porter Glover; Gerd Wallukat; Katrin Wenzel; Kathy Cockrell; James N Martin; Michael J Ryan; Ralf Dechend
Journal:  Hypertension       Date:  2009-08-24       Impact factor: 10.190

6.  Methotrexate: long-term safety and efficacy in an Australian consultant rheumatology practice.

Authors:  N Varatharajan; I G S Lim; A Anandacoomarasamy; R Russo; K Byth; D G Spencer; N Manolios; G B Howe
Journal:  Intern Med J       Date:  2009-04       Impact factor: 2.048

Review 7.  The inflammasomes: mechanisms of activation and function.

Authors:  Eicke Latz
Journal:  Curr Opin Immunol       Date:  2010-01-08       Impact factor: 7.486

Review 8.  Role of the adaptive immune system in hypertension.

Authors:  David G Harrison; Antony Vinh; Heinrich Lob; Meena S Madhur
Journal:  Curr Opin Pharmacol       Date:  2010-02-17       Impact factor: 5.547

9.  Interleukin 17 promotes angiotensin II-induced hypertension and vascular dysfunction.

Authors:  Meena S Madhur; Heinrich E Lob; Louise A McCann; Yoichiro Iwakura; Yelena Blinder; Tomasz J Guzik; David G Harrison
Journal:  Hypertension       Date:  2009-12-28       Impact factor: 10.190

10.  Role of the T cell in the genesis of angiotensin II induced hypertension and vascular dysfunction.

Authors:  Tomasz J Guzik; Nyssa E Hoch; Kathryn A Brown; Louise A McCann; Ayaz Rahman; Sergey Dikalov; Jorg Goronzy; Cornelia Weyand; David G Harrison
Journal:  J Exp Med       Date:  2007-09-17       Impact factor: 14.307

View more
  1 in total

1.  Neutrophil extracellular traps accelerate vascular smooth muscle cell proliferation via Akt/CDKN1b/TK1 accompanying with the occurrence of hypertension.

Authors:  Xinhui Fang; Ling Ma; Yanfu Wang; Fang Ren; Yanqiu Yu; Zhengwei Yuan; Hongquan Wei; Haipeng Zhang; Yingxian Sun
Journal:  J Hypertens       Date:  2022-08-03       Impact factor: 4.776

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.